HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

Caliper Not Without Risks

November 25, 2008 | Comments: 0
Recommended this article (1)
Print    Share

Caliper Life Sciences, Inc. (CALP - Analyst Report) develops and commercializes life science instruments and related consumables and services for use in drug discovery and development and other life sciences research. Caliper makes specialized LabChips (roughly one-inch in diameter) that miniaturize, integrate, and automate laboratory functions, with the intention of enhancing the capabilities,
and reducing the size of laboratories.

CALP reported Q3 cash EPS that beat our estimate by $0.04 on revenue that was lower than our forecast. We lowered our FY08 revenue and cash EPS estimates and also lowered our FY09 revenue and cash EPS estimates. Management lowered its revenue guidance for 2008.

The company restructured its operations into three strategic business units. This restructuring has resulted in product line divestitures and additional cost savings.

Risk exists in top line and execution. Our target price is based on roughly 0.4x FY09 revenue estimate.

Read the full analyst report on CALP.


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!

More Zacks Resources

Market Summary Nov 23, 2009 18:25 pm ET
DJIA 10450.95  132.79 1.29%
NASD 2176.01  29.97 1.40%
S&P 500 1106.24  14.86 1.36%
Sponsored Links